Shield Therapeutics is focused on the development and commercialisation of Feraccru, a CHMP-approved oral formulation of iron positioned for the treatment of iron deficiency (ID) with or without anaemia. In 2018, out-licensing Feraccru to Norgine re-established an active salesforce in core EU5 territories and provided Shield with a cash injection of £11m. Additional near-term revenue (royalties and milestones) is expected as Norgine continues rollout of Feraccru across Europe in 2020. I
19 Feb 2019
Shield Therapeutics - Fortified for growth
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Shield Therapeutics - Fortified for growth
Shield Therapeutics Plc (STX:LON) | 1.5 0 (-3.7%) | Mkt Cap: 11.5m
- Published:
19 Feb 2019 -
Author:
Dr Susie Jana -
Pages:
18
Shield Therapeutics is focused on the development and commercialisation of Feraccru, a CHMP-approved oral formulation of iron positioned for the treatment of iron deficiency (ID) with or without anaemia. In 2018, out-licensing Feraccru to Norgine re-established an active salesforce in core EU5 territories and provided Shield with a cash injection of £11m. Additional near-term revenue (royalties and milestones) is expected as Norgine continues rollout of Feraccru across Europe in 2020. I